Small caps: Allergy Therapeutics, Goldplat, Avacta

20th Sep 2010 14:41

Hay fever treatment specialist Allergy Therapeutics posted an operating profit for the year to June of £1.5m (2009: loss £5.1m) and cut losses to £116,000 from £11.4m. "On the regulatory front, the submission in March 2009 of Pollinex Quattro Grass, our ultra-short course four injection grass allergy vaccine, remains under assessment by the Paul-Ehrlich Institute in Germany. Marketing approval is planned for Germany in early 2011 and subsequently elsewhere in Europe. This will enable Allergy Therapeutics to accelerate sales growth in its current markets as well as entering new European markets, " it said.Miner Goldplat's profits fell to £1.94m from £2.4m in the year to June. The South African and Ghanaian gold recovery plants continuing to perform strongly while production totalled 21,461 ounces of gold against 21,068 oz.Avacta has entered into an agreement with EV (Medical Screening) Limited for the exclusive worldwide rights to Avacta's laser based breath diagnostics technology.Shares in Avocet Mining have been boosted by positive drilling results a gold project in Belahouro district in Burkina Faso.Similarly, Norseman Gold was is in demand after saying it has made progress with its project in the Eastern Goldfields of Western Australia.Losses widened at EMED Mining in the half year to June 30, but the company is cheered by strong copper prices, which it hopes to benefit from once its Rio Tinto Mine starts production in Spain next year.The company posted a pre-tax loss of €5.3m against a €4.3m deficit in the same period the previous year.HaiKe Chemical Group, which makes petrochemicals, speciality chemicals and biochemicals, was hit hard by the higher oil price in the six months to June 30.Despite revenue rising by 78.7% from the same period last year to $467.2m, the China-focused company posted a loss of $21.2m against a profit of $10.8m over the same period the previous year.